U
IMUC

UBS’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

UBS’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7K Sell
200
-63
-24% -$2.43K ﹤0.01% 9243
2014
Q2 		$12K Sell
263
-170
-39% -$8.2K ﹤0.01% 8750
2014
Q1 		$21K Sell
433
-87
-17% -$4.25K ﹤0.01% 8055
2013
Q4 		$19K Buy
520
+280
+117% +$26.5K ﹤0.01% 8257
2013
Q3 		$25K Buy
240
+225
+1,500% +$24.7K ﹤0.01% 7799
2013
Q2 		$1K Buy
+15
New +$1.44K ﹤0.01% 10148

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UBS's IMUC Position: Q3 2014 in Review

UBS increased its ImmunoCellular Therapeutics, Ltd. (IMUC) stake by 4,576% in Q3 2014, buying an estimated $44.1K and bringing the position to 1,169 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #7073.

UBS first reported a position in IMUC in Q2 2013 and has held it in 6 quarters since. The position peaked at $186K in Q3 2013. 39 funds tracked by Wall St. Rank hold IMUC as of Q3 2014.

  • UBS held 1,169 shares of ImmunoCellular Therapeutics, Ltd. worth $42K as of Q3 2014.
  • UBS bought 1,144 ImmunoCellular Therapeutics, Ltd. shares in Q3 2014, an estimated $44.1K.
  • ImmunoCellular Therapeutics, Ltd. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7073 holding.
  • UBS first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and has held it in 6 quarters since.
  • UBS's ImmunoCellular Therapeutics, Ltd. position peaked at $186K in Q3 2013.
  • 39 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.